Skip to main content
Sign In

University of Colorado Denver

​​​​​​​​​ ​
 

Peter Anderson, PharmD

Associate Professor, Department of Pharmaceutical Sciences


Mailing address:

University of Colorado School of Pharmacy
Mail Stop C238
12850 E. Montview Blvd. V20-4101
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4101

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Fourth Floor
Room 4410A/D

Contact:

Training and Education:

  • 1998-2001 Post-Doctoral Research Fellowship Clinical Pharmacology of Antiviral Compounds; University of Minnesota, Minneapolis
  • 1994-1998 Doctor of Pharmacy, University of Minnesota, Minneapolis, College of Pharmacy.
  • 1985-1991 Bachelor of Science in Biology, University of Minnesota, St Paul. 

    Clinical / Research Interest:

    The clinical pharmacology of antiviral medications with a focus on HIV. Current projects include intracellular pharmacology of nucleoside analogs for HIV and pharmacogenetics of antiretroviral agents.

    Teaching:

  • Professional Fall: Clinical Science Foundations - Pharmacokinetics (Lecturer)
  • Professional Fall: IOS XI Infectious Diseases (Lecturer)
  • Graduate Fall: Fundamentals of Pharmaceutical Sciences (Course Director)

    Representative Publications:

    • Grant RM, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med. 2010 Dec 30;363(27):2587-99. Epub 2010 Nov 23.
    • Wempe MF and Anderson PL. Atazanavir metabolism according to CYP3A5 status: An in vitro - in vivo assessment. Drug Metabolism and Disposition.  2011 Mar;39(3):522-7. Epub 2010 Dec 9.
    • Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacologic considerations for tenofovir and emtricitabine to prevent HIV infection. . J Antimicrob Chemother. 2010. Nov 30. [Epub ahead of print]
    • Enomoto L, Anderson PL, Edelstein C, Weinberg A. Effect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions. AIDS Research and Human Retroviruses. 2010. Oct 7. [Epub ahead of print]
    • Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, and MaWhinney S. Atazanavir pharmacokinetics in genetically-determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov;64(5):1071-9
    • Anderson PL, King TM, Zheng JH, MaWhinney S. Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro. J Antimicrob Chemother. 2008 Oct;62(4):738-45.
    • Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-infected Patients.  JAIDS 2008; 47(3):298-303.
    • Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS. 2007 Sep;21(14):1849-54.
    • Anderson PL,  Lamba J, Aquilante CL, Schuetz E, and Fletcher CV . Pharmacogenetic characteristics of indinavir, ZDV, and 3TC in HIV-infected adults: A pilot study. JAIDS. 2006 Aug 1;42(4):441-449.
    • Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of Nucleoside- and Nucleotide- analogue reverse-transcriptase Inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004; 38:743–53.
  • ​​